Skip to main content
PLOS One logoLink to PLOS One
. 2021 Jan 28;16(1):e0245915. doi: 10.1371/journal.pone.0245915

Risk factors associated with congenital anomalies among newborns in southwestern Ethiopia: A case-control study

Soressa Abebe 1,*, Girmai Gebru 1, Demisew Amenu 2, Zeleke Mekonnen 3, Lemessa Dube 4
Editor: Linglin Xie5
PMCID: PMC7843017  PMID: 33508017

Abstract

Introduction

Human embryo is well protected in the uterus by the embryonic membrane, although teratogens may cause developmental disruptions after maternal exposure to them during early pregnancy. Most of the risk factors contributing to the development of congenital anomalies are uncertain; however, genetic factors, environmental factors and multifactorial inheritance are found to be risk factors. Regardless of their clinical importance, there are little/no studies conducted directly related to predisposing risk factors in southwestern Ethiopia.

Objective

The study aimed to determine the associated risk factors with congenital anomalies among newborns in southwestern Ethiopia.

Methods

Case—control study was conducted on newborns and their mothers in six purposively selected hospitals in southwestern Ethiopia from May 2016 to May 2018. Data was collected after evaluation of the neonates for the presence of congenital anomalies using the standard pretested checklist. The data was analyzed using SPSS version 25.0. P <0.01 was set as statistically significant.

Results

Risk factors such as unidentified medicinal usage in the first three months of pregnancy (AOR = 3.435; 99% CI: 2.012–5.863), exposure to pesticide (AOR = 3.926; 99% CI: 1.266–12.176), passive smoking (AOR = 4.104; 99% CI: 1.892–8.901), surface water as sources of drinking (AOR = 2.073; 99% CI: 1.221–3.519), folic acid supplementation during the early pregnancy (AOR = 0.428; 99% CI: 0.247–0.740) were significantly associated with the congenital anomalies.

Conclusions

In this study, risk factors such as passive smoking, exposure to pesticides, chemicals and use of surface water as a source of drinking during early pregnancy had a significant association with congenital anomalies. There is a need to continuously provide health information for the community on how to prevent and control predisposing risk factors.

Introduction

Intrauterine development can be considered as normal development as well as abnormal development. Abnormal development occurs because of the interference of normal development from genetic disorders, environmental factors, and the combination of both genetic and environmental factors during the critical period of embryogenesis. This leads to abnormal cytogenesis, histogenesis and morphogenesis with which the neonate born with a defect known as a congenital anomaly (CA) [1,2].

CA begins to emerge as one of the major childhood health problems as well as a cause of infant mortality and morbidity throughout the world especially in developing countries [3]. In most cases, infants with malformation do not survive, more than 70% die in the first month of life. Moreover, treatment and healing of children with congenital malformations are costly and complete recovery may be impossible [48].

However, most of the risk factors of CAs are uncertain (40–60%) genetic factors, environmental factors, and multifactorial inheritance are among risk factors that lead to abnormal prenatal development [4]. Maternal chromosomal abnormalities which can be defined as numerical and structural abnormalities of the chromosomes cause a genetic disorder. Besides, a single gene mutation also contributes to genetic related birth defects [2].

CAs are a major cause of prenatal and neonatal deaths worldwide [1]. The prevalence rates of all genetic birth defects combined range from a high of 82/1,000 live births in low–income regions to a low of 39.7/1,000 live births in high–income regions [1,9].

The human embryo is well protected in the uterus by the extra-embryonic membranes, although teratogens/ environmental factors may cause developmental disruptions after maternal exposure to them in a specific period of embryogenesis during the critical period in early pregnancy [4]. The organs or parts of an embryo are most sensitive to environmental factors during periods of rapid differentiation leading to abnormal development or malformation of those organs [10,11].

Environmental factors that are considered as being potential risk factors in causing congenital malformation include maternal infection, maternal age and maternal drug intake during the critical period of embryogenesis and substances such as, caffeine, nicotine, commonly used medicines, maternal nutritional and health status, maternal exposure to hazardous waste and maternal alcohol intake during early pregnancy [1,2]. Moreover, parental race, parental socioeconomic status, hyperthermia during early pregnancy and maternal diabetes as well as obesity are also considered to be associated risk factors in causing developmental malformations [2].

About 10% of CAs are caused due to environmental factors. The risk identification for exposure to such factors is of paramount importance as some forms of CAs can be prevented to a large extent if identified and appropriate caution is taken [1].

Chemical substances such as mercury, lead and arsenic are known to lead to the development of congenital abnormalities [10]. Mercury, which is found in some types of fish, has been linked with the development of neurological problems resembling cerebral palsy as well as mental retardation. Lead has been associated with fetal growth restriction and neurological disorders [2].

Other environmental factors such as radiation also contribute to the formation of abnormal development. For example, X-rays can cause problems with fetal development, such as spina bifida, cleft palate, blindness, abnormalities of the arms and legs, or microcephaly. But the type of malformation or abnormality that develops depends on the dose of X-ray radiation that the pregnant woman is exposed to during early pregnancy [1,4].

Multifactorial inheritances, referring to the additive effects of many genetic and environmental factors, are responsible for several developmental disorders resulting in congenital malformations [11,12]. Multifactorial inheritances linked to the causation of CAs in humans include gene-gene and gene-environment interactions and have been demonstrated in mouse models of neural tube defects [11].

CAs are the fifth leading cause of years of potential life loss and a major cause of morbidity and mortality throughout children of the world. Regardless of their clinical importance, there are little/no studies conducted directly related to predisposing risk factors including genetic diseases/disorders that could demonstrate the incidence and prevalence level of these conditions and related risk factors in Ethiopia. Hence, to realize the organization of community genetic services program in primary health care in Ethiopia, conducting hospital-based studies that may give a clear picture of predisposing risk factors associated with a CA is needed to be evaluated. Furthermore, there is a paucity of information regarding the predisposing risk factors associated with CAs specifically in southwestern Ethiopia. Thus, the present study was carried out to investigate risk factors associated with CAs in southwestern Ethiopia.

Subjects and methods

Study area and period

The study was conducted in southwestern Ethiopia from May 2016 to May 2018 for two years during which there were 35,080 deliveries. Southwestern Ethiopia mainly belongs to the Oromia regional state–the largest region with the largest population sizein Ethiopia. Most of the population in the southwestern region are Muslims, Orthodox, Protestants, and some others.

Design of the study and sample size

The case-control study design was used to investigate the exposure status of associated risk factors for CAs in case and control newborns (alive and stillbirth) in six out of seven hospitals in southwestern Ethiopia. Cases were births (fresh still or alive) with minor and major CAs, while the controls were births (fresh still or alive) without any CAs. Two hundred fifty-one cases and 887 controls were used with a total sample size of 1138. The sample size was calculated using a case-control ratio of 1:4. The proportion difference approach with the desired confidence level of 99%, 80% power, and a 1% significant level, assuming that the Odds ratio expected to be 2 [13]. Whenever a case occurred, four controls were randomly selected from the existing newborns without CAs at the maternity ward immediately after the occurrence of the case/cases.

Source and study population

All new births that were delivered and their corresponding mothers who had given birth in the sampled hospitals in southwestern Ethiopia during the study period were the source population for the study. Source populations for cases were all births (still or live) with CAs and mothers who had a neonate with CAs in the selected hospitals during the study period. Source populations for controls were all births (still and live births) without any CAs and their corresponding mothers in the selected hospitals during the study period. All the still and alive born neonates in the selected hospitals during the study period were included in the study.

Inclusion criteria

Cases

  • Births (live birth or fresh stillbirth) either singletons or multiple at terms of gestational age with any CAs or disorders.

Controls

  • Births (live birth or fresh stillbirth) either singletons or multiple at terms of gestational age without any congenital disorders, but in the same geographical location with the cases.

Exclusion criteria

Cases and controls

A mother that came from a different region was excluded from both case and control.

Sampling techniques

There were seven functional hospitals in the study area. We have purposively included all except one in the study after reviewing the hospital record for CAs and capacity to assess the defects among the newborns. These are Jimma University specialized teaching hospital, Shanan Gibe hospital, Agaro hospital, Limmu Genet hospital, Nekemte hospital, and Mettu Karl hospital. Then cases and controls were selected consecutively.

Data collection and measurement

Newborns, either fresh stillbirth or live birth in the selected hospitals during the study period were evaluated for the presence of any CAs by trained health professionals. A standard pretested checklist was used to assess every live and fresh stillbirth at selected hospitals. The assessment of CAs was conducted by trained residents, general practitioners, and midwives at obstetrics and gynecology delivery wards in study hospitals. The data were collected from the mothers of cases and controls via face—to—face interviews using a structured questionnaire containing variables regarding socio-demographic, maternal characters, neonate characters, and other associated risk factors.

Study variables

Dependent variables

  • Congenital anomalies (yes/no)

  • Types of congenital anomalies

Independent variables

Maternal age, socioeconomic status, educational background, maternal health status (medical disorder such diabetes mellitus), maternal exposure to drugs, maternal exposure to infection, maternal exposure to pesticides, medications, alcohol, tobacco, khat and waste disposal areas and sources of drinking water, mode of deliveries, gestational age, sex and birth weight of the neonate were considered as associated risk factors for the CAs (malformation) and were the focus of the study.

Data management and analysis

The collected data were checked regularly on a daily basis, whenever the case occurred, by the data collectors and further superintended by the principal investigator and supervisors for its completeness and correctness. The collected data were cleaned, coded and entered into Epi Data manager computer software and transferred to SPSS Version 25.0 for analysis. The outcome of fetal birth disorder was determined to intermesh with the mode of deliveries. CAs were classified according to ICD-10 (International Classification of Diseases– 10). Total prevalence was calculated by dividing the numerator (registered cases of CA) by the relevant denominator (total live and stillbirths) for the same period of time at the same place. Overall data were calculated using frequency, cross-tabulation, binary and multiple logistic regressions. Exposure variables with P-value ≤0.2 on bivariate analysis were entered into a multivariable logistic regression model to evaluate the association between the exposures and CAs. The COR and AOR with their 99% confidence intervals and the P-value as well as the results of the findings were presented in the form of text and table. The 99% CI not including the null value was used to declare statistical significance.

Quality assurance

The questionnaire was prepared in English then translated into Amharic and Afaan Oromo and translated back into English by another person to check its semantic equivalence. The questionnaire was pre-tested on 5% of the sample size in the non-selected health center district. Training was given to data collectors and evaluators. The completed questionnaire was checked for consistency and completeness by the principal investigator and supervisors.

Ethical clearance

Ethical approval was obtained from the Addis Ababa University, College of Health Sciences, Institutional Review Board, meeting Ref. No. 005/16, dated May 2016. Supportive letters were written and submitted to all study hospitals’ administrators. Then data collections were started after permissions were obtained from the medical directors of each hospital. The study procedure and its aim were disclosed to participants. All the study participants were informed that participation is voluntary and can be withdrawn at any time. Not being volunteers cannot affect the service that they did get from the hospital. Written and signed consent was obtained from all study participants before administering the questionnaires and face—to—face interviews. The participants did not write their names on the questionnaires for confidentiality and no identifying information was recorded by participants. The data were coded, stored in a safe and secure location. The data were never exposed to anyone and only used for the study purpose to maintain confidentiality.

Results

In the present study, the sample consisted of 251 newborns with CAs and 887 newborns without CAs. The case to control ratio used was 1:4. Twenty-four types of CAs were identified with total anomalies of 290 during the study period. Of 887 controls, 628(55.2%) were male and 510 (44.8%) were female newborns. 128 (51.0%) and 123 (49.0%) of the cases were male and female, respectively. About 212 (84.5%) of the CAs identified were single/isolated, whereas 39 (15.5%) were multiple—two or more anomalies on a single case involving two or more organ systems. The overall incidence rate of CAs in southwestern Ethiopia was 71.6 per 10,000 births. The overall frequency of CAs by organ system is shown in Table 1.

Table 1. Frequency of congenital anomalies by organ/organ system among study subjects in southwestern Ethiopia.

Types of congenital anomalies Frequency %
Neural tube defects 177 15.55
Musculoskeletal defects 46 4.04
Gastrointestinal defects 16 1.41
Urogenital defects 6+1* = 7 0.62
CHD 1 0.09
Genetic disorder: Down syndrome, Achondroplasia 4 0.35
No congenital anomalies/controls 887 77.94
Total 1138 100

CHD: Congenital heart defect;1*: Ambiguous genitalia.

Socio-demographic characteristics of the study subjects

The mean age for case and control mothers was 26 years old. The maternal age of the cases was ranging from 17 to 42 years. Similarly, the maternal age of controls was ranging from 15 to 40 years old. Likewise, the paternal age range for cases and controls was 20 to 61 years old and 19 to 66 years old, respectively.

About 26.0% and 21.0% of mothers of the cases and controls were below 20 years old, respectively. Whereas, 32.4% and 37.5% of mothers of the cases and controls were in the age group of 21 to 24 years old, respectively. 38.0% and 37.4% of the mothers of the cases and controls were in the age group of 26 to 35 years old, respectively. Lastly, about 3.6% of both mothers of the cases and controls were ≥36 years old (Table 2).

Table 2. Socio-demographic characteristics of the study subjects with or without CAs in southwestern Ethiopia.

Characteristics Cases (n = 251) Controls (n = 887) Total (n = 1138)
Frequency % Frequency % Frequency %
Age of the mother < = 20 65 26.0 189 21.4 254 22.4
21–25 81 32.4 331 37.5 412 36.4
26–35 95 38.0 330 37.4 425 37.5
> = 36 9 3.6 32 3.6 41 3.6
Maternal education Illiterate 120 47.8 327 37.0 447 39.4
Literate 131 52.2 556 63.0 687 60.6
Maternal educational level 1–4 (primary) 13 9.9 21 3.8 34 5.0
5–8(junior) 46 35.1 169 30.6 215 31.5
9–12 (high school) 49 37.4 211 38.2 260 38.1
13 and above (Higher education) 23 17.6 151 27.4 174 25.5
Religion Muslim 164 65.3 535 60.6 699 61.6
Orthodox 48 19.1 222 25.1 270 23.8
Protestant 39 15.5 126 14.3 165 14.6
Average monthly income in USD <27 37 26.4 89 18.3 126 20.1
27–135 95 67.9 355 72.9 450 71.8
162–270 6 4.3 36 7.4 42 6.7
297 and above 2 1.4 7 1.4 9 1.4
Maternal occupation Housewife 151 64.8 503 58.6 654 59.9
Farmer 34 14.6 95 11.1 129 11.8
Employee 29 12.4 177 20.6 206 18.9
Merchant 11 4.7 72 8.4 83 7.6
Unemployed 8 3.4 11 1.3 19 1.7
Fathers age < = 25 55 22.6 236 29.7 291 28.0
26–34 104 42.8 327 41.1 431 41.5
> = 35 84 34.6 232 29.2 316 30.4

USD: United State Dollar.

Among the mothers of cases and controls, about 60.6% had formal education while 39.4% of the mothers were illiterate. 5% had primary education, 31.5% had junior level, 38.1% had attained high school level and 25.5% had joined higher education. In terms of religious inference, 61.6%, 23.8%, and 14.6% were Muslims, Orthodox, and Protestants, respectively.

71.8%, 6.7%, and 1.4% had a monthly income of twenty-seven to one hundred thirty-five, one hundred sixty-two to two hundred seventy and two hundred ninety seven and above USD, respectively. Among the mothers of both cases and controls, 59.9% were housewives, 11.8% were farmers, 18.9% were governmental employees, 7.6 were merchants and 1.7% were unemployed. The socio-demographic characteristics of the study participants of cases and controls are shown in Table 2.

About 7.2% of the mothers of the cases and 2.9% of mothers of controls had no antenatal care visit. Regarding the birth order of a case, 37.2%, 21.1%, 14.2%, and 27.0% were the first, the second, the third, the fourth, and above (4+) babies to their family, respectively. For those of the control group, about 43.6%, 24.8%, 13.0%, and 18.5% were the first, second, third, fourth, and above (4+) babies to their family, respectively.

Regarding gestational age, about 47.6% of cases and 19.9% of the controls were classified as preterm (<37 weeks). The differences between the cases and the controls were statistically significant with an Odds ratio of 2.461; 99% CI: 1.806–3.299, P-value < 0.001, revealing that cases are more likely to have a premature birth. Hence, premature births were associated with the presence of CA. On the contrary, 40.8% of the cases and 58.1% of the controls attained their full-term gestational age (Table 3).

Table 3. Reproductive history of mothers who gave birth to a child with or without CAs in southwestern Ethiopia.

Characteristics Case (n = 251) Control (n = 887) Total (1138)
Frequency % Frequency % Frequency %
Antenatal care follow up
No antenatal care 18 7.2 26 2.9 44 3.9
1 to 3 visits 138 55.5 311 35.2 449 39.7
Minimum of 4 visits 94 37.6 546 62.0 640 56.5
Parity 0 & 1 13 54.5 537 61.7 671 60.1
2 & 3 68 27.6 217 24.9 285 25.5
> = 4 44 17.9 117 13.4 161 14.4
Gravid 0 & 1 90 36.4 377 43.4 467 41.8
2 & 3 83 33.6 321 36.9 404 36.2
> = 4 44 30.0 171 19.7 245 22.0
Onset of labor Spontaneous 197 79.1 799 91.6 996 88.8
Induced 52 20.9 73 8.4 125 11.2
Mode of delivery Vaginal 208 83.2 629 71.5 837 74.1
Scissoral 42 16.8 251 28.5 293 25.9
Gestational age Preterm 119 47.6 176 19.9 295 26.0
Term 102 40.8 514 58.1 616 54.3
Post-term 29 11.6 195 22.0 224 19.7
Sex of the newborn Male 128 51.0 500 56.6 628 55.4
Female 123 49.0 383 43.4 506 44.6
Birth weight in gram <2500 100 39.8 72 8.2 172 15.2
> = 2500 151 60.2 811 91.8 962 84.8
Birth outcome Live birth 96 38.4 836 94.8 932 82.3
Stillbirth 154 61.6 46 5.2 200 17.7
Types of birth outcome Single 236 94.8 836 96.3 1072 96.0
Twin 13 5.2 32 3.7 45 4.0
Birth order 1st 92 37.2 380 43.6 472 42.2
2nd 52 21.1 216 24.8 268 23.9
3rd 35 14.2 113 13.0 148 13.9
4th and greater 67 27.0 163 18.5 230 19.5

As shown in Table 3, 39.8% and 8.2% of the cases and controls were born with low birth weight (<2500 g), respectively. About 61.6% and 5.2% of the cases and controls were sillbirth, respectively. There was a significant difference between the cases and the controls revealing that the presence of CAs could affect the neonatal outcome. Hence, more stillbirths occurred in cases than controls.

In the present study, about 12.4% and 9.2% of mothers of the cases and controls had a history of abortion. However, the difference between mothers of the cases and controls were not statistically significant. 9.3% and 7.9% of mothers of the cases and controls had a history of stillbirth, respectively. About 3.0% and 0.8% of the cases and control mothers had a birth history of CAs, respectively indicating that there were no statistically significant differences between the cases and the control mothers (COR = 3.607; 99% CI: 0.899–14. 471; P-Value = 0.017) (Table 4).

Table 4. Obstetrics history of the study subjects in southwestern Ethiopia.

Variables Cases Controls OR (99% CI) P-value
Number % Number %
History of abortions Yes 29 12.4 81 9.2 1.467 (0.827–2.601 0.085
No 205 87.6 799 90.8 1
History of stillbirths Yes 22 9.3 70 7.9 1.229 (0.649–2.330) 0.405
No 215 90.7 811 92.1 1
Previous history of a congenital anomaly Yes 7 3.0 7 0.8 3.607 (0.899–14.471) 0.017
No 230 97.0 877 99.2 1
History of congenital anomalies in the family Yes 9 3.8 15 1.7 2.685 (0.949–7.595) 0.014
No 225 96.2 861 98.3 1

OR: Odds ratio; CI: Confidence interval.

About 3.8% of mothers of the cases and 1.7% of controls had a history of congenital malformation in their family, revealing that there were statistically significant differences between the case mother and control mothers (COR = 2.685; 99% CI: 0.949–7.595; P-value = 0.014).

Associated risk factors with congenital anomalies

In the present study, there were maternal illnesses in 113 (45.0%) mothers of the cases and 373 (42.2%) of controls. 15 (6.0%) mothers of the cases and 48 (5.4%) of the controls had a history of taking alcohol during early pregnancy/first trimester of pregnancy. 3 (1.2%) mothers of the cases and 2(0.2%) controls mothers had a history of smoking cigarettes.

Passive smokers were observed in 28(11.2%) mothers of the cases and 28 (3.2%) of the controls. 5(2.0%) mother of the cases and 5(0.6%) of the controls had a history of exposure to radiation. Exposure to pesticides and the use of different antibiotics during their early pregnancy/ the first three months were observed in 13(5.2%) and 79 (53.4%) mothers of the cases, respectively. Whereas, 12(1.4%) and 261(46.9%) of the controls had exposure to pesticides and used different antibiotics during their early pregnancy, respectively.

57(22.7%) and 77(8.7%) of mothers of the cases and mothers of the controls had experiences of using unidentified medicine and drugs during the first three months of their pregnancy, respectively. Similarly, 47(19.0%) and 38(15.3%) mothers of the cases and 144(16.4%) and 172(19.5%) of the controls had a history of using drugs in the second and third trimester of their pregnancy, respectively (Table 5).

Table 5. Bivariate analysis of environmental, family history, exposure to different chemicals, and maternal illness of the study subjects in southwestern Ethiopia.

Variables Response Cases (n = 251) Controls (n = 887) COR 99% CI P-value
Number % Number % Lower Upper
Folic acid use Yes 89 35.5 434 49.2 0.563 0.385 0.825 0.000
No 162 64.5 449 50.8 Ref 1
Drinking alcohol Yes 15 6.0 48 5.4 1.115 0.508 2.446 0.721
No 234 94.0 833 94.6 1
Smoking cigarettes Yes 3 1.2 2 0.2 5.317 0.503 56.242 0.068
No 248 98.8 870 99.8 1
Passive smoking Yes 28 11.2 28 3.2 3.852 1.884 7.875 0.000
No 223 88.8 855 96.8 1
Exposure to X–rays Yes 5 2.0 5 0.6 3.586 0.696 8.482 0.045
No 244 98.0 873 99.4 1
Exposure to pesticides Yes 13 5.2 12 1.4 4.012 1.406 11.446 0.001
No 236 94.8 871 98.6 1
Diabetes mellitus Yes 4 1.6 1 0.1 14.341 0.800 256.981 0.017
No 246 98.4 880 99.9 1
Maternal illness Yes 113 45.0 373 42.2 1.118 0.772 1.620 0.438
No 138 55.0 510 57.8 1
Use of antibiotics Yes 79 53.4 261 46.9 1.303 0.808 2.100 0.153
No 69 46.6 296 53.1 1
Have asthma Yes 4 1.6 15 1.7 0.648 0.127 3.309 0.493
No 247 98.8 852 98.3 1
Drug use during the first three months Yes 57 22.7 77 8.7 3.091 1.884 5.070 0.000
No 194 77.3 806 91.3 1
Drug use between 4th and 6th months Yes 47 19.0 144 16.4 1.197 0.741 1.932 0.334
No 201 81.0 736 83.6 1
Drug use during the last three months Yes 38 15.3 172 19.5 0.747 0.451 1.237 0.136
No 210 84.7 709 80.5 1
Drinking coffee during pregnancy Yes 218 92.4 780 88.3 1.353 0.716 2.554 0.221
No 18 7.6 103 11.7 1
Use of khat during pregnancy Yes 23 9.2 54 6.1 1.556 0.797 3.040 0.089
No 228 90.8 1
Hypertension disorder Yes 16 6.4 52 5.9 1.091 0.510 2.335 0.767
No 234 93.6 829 94.1 1

Reference = 1.

162(64.5%) mothers of the cases and 449(50.8%) of controls were not used folic acid supplementation during the index pregnancy, respectively. Likewise, diabetes mellitus was observed in 4 (1.6%) mothers of cases and 1(0.1%) in controls. Besides, 16(6.4%) mothers of the cases and 52(5.9%) of the control had hypertension before and during pregnancy. Asthma was observed in 4 (1.6%) mothers of the cases and 15(1.7%) of the controls.

Selected variables were entered in to the COR analysis to identify crude risk estimates. Of these, smoking cigarettes during pregnancy (COR = 5.317; 99% CI: 0.503–56.242, P- value = 0.068), passive smoking (COR = 3.852; 99% CI: 1.884–7.875, P-value = <0.001), exposure to radiation (X–rays) in the early pregnancy (COR = 3.586; 99% CI: 0.696–8.482, P- value = 0.045), exposure to pesticides (COR = 4.012; 99% CI: 1.406–11.446, P–value <0.001), diabetic mellitus (COR = 14.341; 99% CI: 0.800–256.981, P- value = 0.017), use of unidentified medication and drugs in the first three months of pregnancy (COR = 3.091; 99% CI: 1.884–5.070, P–value < 0.001) were associated with CAs in the crude Odds ratio analysis and may be responsible for the occurrences of CAs. Differently, folic acid (COR = 0.563; 99% CI: 0.385–0.825, P–value < 0.001) was considered to have a protective effect against the occurrence or the development of CAs.

Independent predictors (risk factors) of CAs adjusted for multiple tests

The variables with P- value of 0.2 and below in the bivariate analysis were entered into multivariable logistic regression model adjusted to observe exposure variables association with CAs (Tables 6 and 7). As a result, unidentified drug usage in the first three months of pregnancy (AOR = 3.435; 99% CI: 2. 012–5.863), exposure to pesticides (AOR = 3.926; 99% CI: 1.266–12.176), passive smoking (AOR = 4.104; 99% CI: 1.892–8.901), surface water as sources of drinking (AOR = 2.073; 99% CI: 1.221–3.519), no antenatal care visits (AOR = 2.952; 99% CI:1.166–7.472), 1 to 3 antenatal care visits (AOR = 2.121; 99% CI: 1.390–3.237) were significantly associated with the occurrence of CAs. On the other hand, iron folate / folic acid supplementation during the indexed pregnancy (AOR = 0.639; 99% CI: 0.247–0.740) had a protective effect againstthe development of CAs.

Table 6. Responses of study subjects on possible risk factors for CAs: Multivariable analysis of AOR for associated risk factors of CAs in southwestern Ethiopia.

Variables Cases Controls COR AOR 99% CI
Number % Number % lower upper
Drug use during the first three months of pregnancy Yes 57 22.7 77 8.7 3.076 3.435 2.012 5.863
No 194 77.3 810 91.3 1
Exposure to pesticides Yes 13 5.2 12 1.4 3.998 3.926 1.266 12.176
No 236 94.8 874 98.6 1
Passive smoking Yes 28 11.2 28 3.2 3.834 4.104 1.892 8.901
No 223 88.8 859 96.8 1
Folic acid use Yes 89 35.5 438 49.4 0.568 0.639 0.247 0.740
No 162 64.5 449 50.6 1
History of congenital anomalies Yes 7 2.8 7 0.8 2.303 3.741 0.875 16.006
No 244 97.2 880 99.2 1

CI: Confidence interval; COR: Crude Odds ratio; AOR: Adjusted Odds ratio.

Table 7. Responses of study subjects on possible risk factors for CAs: Multivariable analysis of AOR for associated risk factors of CAs in southwestern Ethiopia.

Charactristics Variables Cases Controls AOR 99% CI
Number % Number % Lower Upper
The water source for drinking Pipe water 169 67.3 716 80.7 1
Underground water 26 10.4 72 8.1 1.492 0.756 2.944
Surface water 56 22.3 99 11.2 2.073 1.221 3.519

Antenatal care follow up
No antenatal visits 18 7.2 26 2.9 2.952 1.166 7.472
1 to 3 visits 138 55.2 310 35.1 2.121 1.390 3.237
Minimum of 4 visits 94 37.6 548 62.0 1

CI: Confidence interval; AOR: Adjusted Odds ratio.

log(oddsofCA)=-1.997+1.234(druguse)+1.368(pesticideexposure)+1.412(passivesmoker)-0.358(folicacid)+1.349(historyofCA+0.729(surfacewater)+1.082(noantenatalcarevisits)+0.752(1to3antenatalcarevisits)

Discussion

Several studies described that the human embryo is well protected in the uterus by the extra-embryonic membranes, although teratogens may cause developmental disruptions after maternal exposure to them in a specific period of organogenesis during the critical period in early pregnancy [10].

In our findings, maternal exposure to actual smoking in crude risk estimate, passive smoking during early pregnancy and exposure to pesticides and herbicides during the critical period of embryogenesis had a significant association with the occurrence of CAs. Moreover, case mothers (1.2%) who were smoking cigarettes during their pregnancy show a 6 times likely increased risk to have neonates with CAs as compared to the control mothers (0.2%).

In line with the present study, studies done in Iraq and Egypt show that maternal smoking either actual or passive smoking in the first three months of pregnancy was strongly associated with the occurrence of birth defects specifically cleft lip with or without cleft palate [14,15]. Congruent with our findings, a study done in southeastern Ethiopia, Bale zone, Oromia region by Mekonnen et al. [16] reported that maternal exposure to pesticides during early pregnancy had a strong association with the occurrence of CAs with the frequency of 13.2% in exposed compared to 4.2% in unexposed.

On the contrary, Taye et al [17] reported in their study done in Addis Ababa and Amhara region that cigarette smoking, either actual or passive smoking, was not associated with CAs. However, several studies, including the present study, showed that there is an association of smoking with the occurrence of CAs [1822]. The difference might be due to the cultural difference in practicing cigarette smoking or staying with a smoker of a country with a geographically different location.

Likewise,Taye et al [17] reported that maternal exposure to chemicals during early pregnancy had a significant association with the occurrence of CAs. Unlike reports from the study done in Addis Ababa and Amhara region where alcohol had a strong association with the risk of having a child with CAs, in our findings, alcohol had no strong association with the occurrence of CAs. This difference might be linked to religious restriction as most of the participants in the present study were Muslims and Protestants who did not drink alcohol.

In our findings, unidentified medicinal use during early pregnancy had a strong association with the occurrence of CAs. Several findings also reported that the use of unidentified medicines during the early period of embryogenesis had a significant association with the occurrence of CAs [17,23,24].

According to our findings, the use of surface water as a source of drinking had a significant association with the occurrence CAs. This might be because chemicals and pesticides added to the surface water through several routes/sources can contaminate the surface water. Using contaminated water as a source of drinking especially during early pregnancy may contribute to the occurrence of CAs as it introduces chemicals that may cross the placenta and disrupt embryonic differentiation during the period of embryogenesis especially in the first 8 weeks of the embryonic period. Our finding agrees with study that reported maternal exposure to drinking water containing nitrate had a risk of having a neonate with CAs [25].

Maternal diseases such as asthma and hypertension showed no association with the existence of CAs in the present study; Besides, maternal diabetes had no significantly associated with the risk of having a neonate with CAs. Incongruent to our findings, several reports from other scientific studies showed that maternal diabetes has been a well established risk factor for CAs and adverse birth outcomes [24,26]. Besides, several findings described that gestational diabetes has a strong association with fetal growth abnormalities. Furthermore, pre-gestational diabetes was identified to be an important risk factor for structural anomalies due to the teratogenic effect of poorly controlled diabetes and is considered to be the most important risk factor during early period of pregnancy, especial during the first 8 weeks, at which active differentiation of organ systems could occur [24,27].

Correa (2016) [28] reported that the embryopathy associated with pre-gestational diabetes mellitus is nonspecific underlying metabolic disorders disturbing morhogenetic process. Accordingly, maternal hyperglycemia results in increased glucose levels in the embryo. Consequently, biochemical aberrations increase oxidative stress that leads to cellular apoptosis.

Oxidative stress results in inhibition of the Pax3 gene especially in the processes of neurulation [28]. Besides, oxidative stress occurred due to the imbalance between the production of oxygen free radicals and the antioxidant defense mechanism of the cells which can generate the irreversible oxidation of DNA leading to apoptosis as a result of enzymatic inactivation [29,30].

The present study showed that there was a strong association between insufficient maternal folic acid supplementation during early pregnancy and the occurrence of CAs. Mothers of the newborn who did get folic acid supplementation during their early pregnancy were strongly protected against having neonates with CAs, specifically neural tube defects. In other words, mothers of the newborns who did not get folic acid supplementation during their early pregnancy were twice as likely to have a baby with CAs. Several studies reported that folic acid supplementation in early pregnancy reduces the occurrence of specific CAs.

In this study, mother of the cases who did not get folic acid supplementation during early pregnancy were 64.5%, revealing that there is poor folic acid supplementation in southwestern Ethiopia. In agreement with our findings, poor folic acid supplementation also observed in the Amhara region, northern Ethiopia [23]. However, a study in the Tigray region, northeastern Ethiopia, revealed that 40.9% participants were adhered to iron folate supplementation [31].

Although, the Federal Ministry of Health and the Regional Health Bureau both promote folic acid supplementation to all women during their indexed pregnancy, most pregnant women have not been provided such supplements yet. This might be because of poor quality of antenatal care in the study region and in Ethiopia in general or communities’ resistance because of lack of knowledge about the importance of folic acid supplementation.

According to the present study, 7.2% of mothers of the cases and 2.9% of mothers of the controls received no antenatal care follow up. The difference between the cases and the controls was statistically significant indicating that the mothers who had not received antenatal care during their pregnancy were strongly associated with having a baby with CAs. Similarly, mothers who had received 1 to 3 antenatal care visits had a significant association with the presence of CAs compared to those who had four and above antenatal care visits.

In our findings, although maternal illness and the use of antibiotics during their pregnancy showed association with the occurrence of CAs, it is not significant statistically. Incongruent with this study, several studies showed that maternal illness and the use of antibiotics during early pregnancy has a strong association with the occurrence of CAs [17,23]. The inconsistency between the present study and other reports might be due to participants fail to report the actual chronic illness that they had during pregnancy.

Although exposure to radiation, especially X–rays, during early pregnancy seems to have an association with the occurrence of CAs in its crude risk estimate, multivariable logistic regression shows no association with the occurrence of the CAs.

In our findings, a maternal history of abortion and stillbirth has no association with the occurrence of CAs. Besides, the mother’s previous birth history of CAs and the birth history of CAs in the family showed no association with the occurrence of CAs. This may have genetic implications. In our findings, more live births were observed in controls than in cases. On the contrary, more stillbirths (61.6%) were observed in cases of newborns with CAs, as compared to the controls (5.2%). A similar report showed that the overall CA-specific stillbirth risk was increased among affected fetuses over the occurrence of stillbirth in the general population in the United State [32,33].

In the present study, about 39.9% of the neonates born with CAs had low birth weight revealing that the presence of CAs can affect the birth weight of the neonate contributing to fetal growth restriction. A study done in northern Ethiopia indicated that parity, low birth weight, gestational age less than 35 weeks, male sex, and lack of antenatal care were significantly associated with CAs [34].

Another study indicated that the prevalence rates of low birth weight and premature birth were significantly greater among infants with CAs than in their non-afflicted counterparts [35]. In agreement with previous studies, the result of the present study indicated that 47.6% of the neonates with CAs were preterm (premature) births where a statistically significant difference was observed between the cases and controls, indicating that the occurrence of CAs contributes to premature delivery with low birth weight.

In this study, socio-demographic characteristics such as maternal educational level, average monthly income, maternal occupation, and paternal age showed no significant association with the occurrence of CAs. Similarly, parity, gravidity, the onset of labor, mode of delivery, and types of birth outcome and birth order of the newborns showed no significant association with the occurrence of CAs.

Strength of the study

First, we used hospitals with high caseloads in southwestern Ethiopia where most cases of CAs were expected. Secondly, a case-control study design was used with a maximum case to control ratio of 1:4. We used trained health professional data collectors, including gynecologists who evaluated the presence of CAs (the cases). The controls were randomly selected from the neonates without CAs whereby two of them selected from newborns delivered 24 hours before the occurrence of the case and the other two were randomly selected from newborns delivered immediately after the occurrence of the case. This might increase the efficiency of the study result in providing predictors or associated factors. Finally, the data analysis was based on all maternal, neonatal, and other associated factors that may contribute to the occurrence of CAs.

Limitation of the study

From existing hospitals in the study regions, only six selected hospitals were used for the study, although cases of CAs were expected in the remaining hospitals and health stations, which may limit generalizability to the wider population of Ethiopia. Secondly, it was a hospital-based study design and might have missed cases of CAs for deliveries that occurred outside the study hospitals within the community. Thirdly, although, structured data collection tools were used, participants recall and self–report of some factors might introduce bias.

Conclusions

In the findings of the present study, maternal socio-demographic factors such as maternal educational level, average monthly income, maternal occupation, and paternal age showed no significant association with the occurrence of CAs. Associated risk factors such as maternal active or passive smoking, exposure to pesticides, exposure to chemicals, use of unidentified medicine during the first three months, use of surface water for drinking had a significant association with the occurrence of CAs. Differently, the use of folic acid during the indexed pregnancy had a significant protective effect against the occurrence of CAs. However, poor folic acid supplementations were observed in the country, Ethiopia. There is a need to continuously provide health information for the community on how to prevent the occurrence of CAs and there is a need to improve the quality of antenatal care follow up as well as folic acid supplementation mainly through food fortifications.

Supporting information

S1 Table. Descriptive analysis (mean and Std.) Deviation of maternal and neonatal characteristics of the study participants in relation to birth weight, gestational age, birth order of the infancy, maternal age, paternal age, maternal average monthly income, party and gravida.

(DOCX)

S2 Table. Interdependent risk factors adjusted for multiple tests.

(DOCX)

S1 Annexes

(DOCX)

S1 File

(SAV)

S1 Syntax

(SPS)

Acknowledgments

We would like to thank all medical wards of each study hospital in southwestern Ethiopia who helped us in providing the information necessary for the study. We would like to extend our sincere thanks to Jimma University specialized hospital, Shanene Gibe hospital, Limu Genet hospital, Mettu Karl hospital, and Nekemte hospital in southwestern Ethiopia, who allowed and helped us during data collection at their centers. Our gratitude extends to our trained data collectors at each hospital of our study area. Our thanks also extend to the staff of the departments of gynecology and obstetrics of each hospital who had direct or indirect inputs for the successful accomplishment of the study.

Data Availability

All relevant data are within the manuscript and its supporting information files.

Funding Statement

This study obtained fund from Addis Ababa University and Jimma University for data collection only. The funders had no role in the study design, data analysis and decision to publish for preparation of the manuscript. No additional external funding was received for this study.

References

  • 1.Butt F, Shahzad R, Pasha I. Pattern and outcome of congenital anomalies and maternal risk factor association. Biomedica. 2013; 29: 234–240. [Google Scholar]
  • 2.Victor BP. Preventing congenital anomalies in developing countries. Community Genet. 2002; 5:61–69. 10.1159/000064632 [DOI] [PubMed] [Google Scholar]
  • 3.Rizk F, Salameh P, Hamadé A. Congenital anomalies: Prevalence and risk factors. Universal Journal of Public Health. 2014; 2(2): 58–63. [Google Scholar]
  • 4.Mohamed AEK, Ehab AAB, Ibrahim L. Pattern of congenital anomalies in newborn: A hospital-based study. Pediatric Reports. 2013; 5(5):20–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Taboo ZA. Prevalence and risk factors for congenital anomalies in Mosul city. The Iraqi Postgraduate Medical Journal. 2012; 22(2): 140–146. [Google Scholar]
  • 6.Amany MA, Shadia A, Azza AA, Hassan MG. Assessment of risk factors for fetal congenital anomalies among pregnant women at Cairo University hospitals. Journal of American Science. 2011; 7(12):899–908. [Google Scholar]
  • 7.Naeimeh T, Katayon Y, Nazila N. The Prevalence of congenital malformations and its correlation with consanguineous marriages. Oman Medical Journal. 2010; 25:37–40. 10.5001/omj.2010.9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Vinceti M, Malagoli C, Rodolfi R, Astolfi G, Rivieri F, Fiorini S, et al. Prevalence at birth of congenital anomalies in a population living around a modern municipal solid waste inciderator. Epidemiology. 2006; 17(6): 272–273. [Google Scholar]
  • 9.Godwin KA, Sibbald B, Bedard T, Kuzeljevic B, Lowry RB, Arbour L. Change in frequency of select congenital anomalies since the onset of folic acid fortifications in Canadian birth defect registry. Can J Public Health. 2008; 99: 271–275. 10.1007/BF03403753 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Shaw GM, Quach T, Nelso V, Carmichae SL, Schaffer DM, Selvin S, et al. Neural tube defects associated with maternal periconceptional dietary intake of simple sugars and glycemic index. American Journal of Clinical Nutrition. 2003; 78:972–978. 10.1093/ajcn/78.5.972 [DOI] [PubMed] [Google Scholar]
  • 11.Neumann PE, Frankel WN, Letts VA, Coffin JM, Copp AJ, Bernfield M. Multifactorial inheritance of neural tube defects: Localization of the major gene and recognition of modifiers in ct mutant mice. Nature Genetics. 1994; 6(4):357–362. 10.1038/ng0494-357 [DOI] [PubMed] [Google Scholar]
  • 12.Graham TP, Driscoll CDJ, Gersony WM, Newburger JW, Rocchini A, Towbin JA. Task Force 2: Congenital heart disease. JACC. 2005; 45 (8): 1326–1333. 10.1016/j.jacc.2005.02.009 [DOI] [PubMed] [Google Scholar]
  • 13.Et. Kelsey. StatCalc—Calculating a sample size with Epi-Info. 2012. p. 1–17.
  • 14.Ameen SK. Alalaf SK, Shabil NP. Pattern of congenital anomalies at birth and their correlations with maternal characteristics in the maternity teaching hospital, Erbil city, Iraq. BMC Pregnancy and Childbirth. 2018; 18:1–8. 10.1186/s12884-017-1633-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Shawky RM, Sadik DI. Congenital malformations prevalent among Egyptian children and associated risk factors. Egyptian Journal of Medical Human Genetics. 2018; 12 (1): 69–78. [Google Scholar]
  • 16.Mekonnen GA, Hordof AG, Kitila TT, Adem S. Modifiable risk factors of congenital malformations in bale zone hospitals, southeast Ethiopia: an unmatched case-control study. BMC Pregnancy and Childbirth. 2020; 20:129 10.1186/s12884-020-2827-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Taye M, Afework M, Fantaye W, Diro E, Worku A. Factors associated with congenital anomalies in Addis Ababa and the Amhara region, Ethiopia: A case-control study. BMC Pediatrics. 2018; 18:142 10.1186/s12887-018-1096-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Grewal J, Carmichael SL, Ma C, Lammer EJ, Shaw GM. Maternal periconceptional smoking and alcohol consumption and risk for select congenital anomalies. Clinical and molecular teratology (birth defects res A). 2008; 82:519–526. 10.1002/bdra.20461 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Alverson CJ, Strickland MJ, Gilboa SM, Correa A. Maternal smoking and congenital heart defects in the Baltimore-Washington infant study. Pediatrics. 2011; 127 (3):647–653. 10.1542/peds.2010-1399 [DOI] [PubMed] [Google Scholar]
  • 20.Little J, Arslan MT, Mossey PA. Smoking and orofacial clefts. A United Kingdom–based case-control study. Cleft Palate Craniofac J. 2004; 41(4):383–386. 10.1597/02-142.1 [DOI] [PubMed] [Google Scholar]
  • 21.Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: A systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update. 2011; 17(5):589–604. 10.1093/humupd/dmr022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Honein MA, Paulozzi LJ, Moore CA. Family history, maternal smoking, and clubfoot: An indication of a gene-environment interaction. Am J Epidemiol. 2000; 152 (7):658–664. 10.1093/aje/152.7.658 [DOI] [PubMed] [Google Scholar]
  • 23.Adane F, Seyoum G. Prevalence and associated factors of birth defects among newborns at referral hospitals in northwest Ethiopia. Ethiop. J. Health Dev. 2018; 32(3):1–6. [Google Scholar]
  • 24.McNeese ML, Selwyn BJ, Duong H, Canfield M, Waller DK. The association between maternal parity and birth defects. Clinical and molecular teratology (birth defects research A). 2015; 103 (2): 144–156. 10.1002/bdra.23360 [DOI] [PubMed] [Google Scholar]
  • 25.Croen LA, Todoroff K, Shaw GM. Maternal exposure to titrate from drinking water and diet and risk of neural tube defects. American Journal of Epidemiology. 2001; 153(4): 325–331. 10.1093/aje/153.4.325 [DOI] [PubMed] [Google Scholar]
  • 26.Reece EA. Diabetes-induced birth defects: what do we know? What can we do? Curr Diab Rep. 2012; 12:24–32. 10.1007/s11892-011-0251-6 [DOI] [PubMed] [Google Scholar]
  • 27.Allen VM, Armson BA, Wilson RD, et al. Teratogenicity associated with pre-existing and gestational diabetes. J ObstetGynaecol. 2007; 29:927–944. 10.1016/S1701-2163(16)32653-6 [DOI] [PubMed] [Google Scholar]
  • 28.Correa A. Pregestational diabetes mellitus and congenital heart defects. Circulation. 2016; 133: 2219–2221. 10.1161/CIRCULATIONAHA.116.022960 [DOI] [PubMed] [Google Scholar]
  • 29.Evers IM, De Valk HW, Visser GH. Male predominance of congenital malformations in infants of women with type 1 diabetes. Diabetes Care. 2009; 32: 1194–1195. 10.2337/dc09-0367 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Lary JM, Paulozzi LJ. Sex differences in the prevalence of human birth defects: a population-based study. Teratology. 2001; 64: 237–251. 10.1002/tera.1070 [DOI] [PubMed] [Google Scholar]
  • 31.Gebremichael TG, Welesamuel TG. Adherence to iron-folic acid supplement and associated factors among antenatal care attending pregnant mothers in governmental health institutions of Adwa town, Tigray, Ethiopia: Cross-sectional study. Plos One. 2020; 15 (1): 1–11. 10.1371/journal.pone.0227090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Dominique H, Eirini N, Sonia HD, Paige W, Rich-Edwards, Janet W., et al. For the national birth defects prevention study risk of stillbirth for fetuses with specific birth defects. Obstetrics and Gynecology. 2020; 135 (1): 133–140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Ehrhardt J, Urquhart K. Stillbirths and birth defects: Michigan 2004‐2011. Michigan Department of Community Health; 2014; 1–4. [Google Scholar]
  • 34.Mekonen HK, Nigatu B,Lamers WH. Birth weight by gestational age and congenital malformations in northern Ethiopia. BMC Pregnancy and Childbirth. 2015; 15 (76): 1–8. 10.1186/s12884-015-0507-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Faal G, Abbasi R,Bijari B. The Prevalence of major congenital anomalies among live births in Birj and Iran. Modern Care Journal. 2018; 15(2): 1–6. [Google Scholar]

Decision Letter 0

Linglin Xie

7 Oct 2020

PONE-D-20-23170

Risk Factors Associated with Congenital Anomalies among Newborns in Southwestern Ethiopia: A case-control study

PLOS ONE

Dear Dr. Geneti,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 12/06/2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Linglin Xie

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include additional information regarding the checklist and questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses.

For instance, if you developed a questionnaire and/or checklist as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

3. Thank you for stating the following in the Competing Interests section:

'The authors, Mr. Soressa Abebe and Dr. Girmai Gebru receive salary from Addis Ababa University, Dr. Demisew Amanu, Professor Zeleke Mekonnen and Mr. Lemessa Dube receive salary from Jimma University.

The authors have declared that no competing interests exist.'

a. Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

b. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

4. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

5. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors’ affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating “current affiliation:….” as necessary).

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Major comments:

This article is a retrospective study on the association between maternal exposure to risk factors during early pregnancy and the development of congenital anomalies. The study was conducted based on data collected from six selected hospitals in southwestern Ethiopia through two years. The data analysis provided exciting data and analysis on the possible correlation between possible risk factors and congenital anomalies.

One issue with the experimental design is the sampling method to select the six hospitals. The authors mentioned that the hospitals were selected purposively based on their capacity to carry out the required assessment. This non-randomness of sampling may sharply limit the generalization of the conclusion to newborns in the whole area. This point has been mentioned in the “Limitation of the Study” section. But without providing more evidence that these hospitals can represent all the hospitals in the area, the authors should be more careful when they tried to generalize the conclusions.

One major issue with the statistical analyses is that the author conducted multiple tests during their studies, while they used a threshold P-value of 0.05 for significance, which is a typical cut-off when doing a single test. I would suggest that they use an adjusted p-value instead to control the false positive rate for this multiple test case.

Also, it would be more informative if a formula for the final regression model with corresponding coefficients was provided beside the descriptions.

Also, there should be a separate section where data availability is described. The authors should show where the original questionnaire and raw data can be found for their readers.

Minor comments:

Table 7: It would be clearer if the variable name is in a separate column from the variable levels.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jan 28;16(1):e0245915. doi: 10.1371/journal.pone.0245915.r002

Author response to Decision Letter 0


10 Dec 2020

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled ‘Response to Reviewers.’

Comment accepted. The rebuttal letter that responds to each point raised by the academic editor and reviewer(s) is included. The letter is uploaded as a separate file and labeled ‘Response to Reviewers’

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled ‘Revised Manuscript with Track Changes’

� Comment accepted. The changes made to the original version is highlighted in orange color in the revised manuscript. The file is labeled as Revised Manuscript with Track Changes’.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled ’‘Manuscript'.

� Comment accepted. The unmarked version of the revised paper without tracked changes labeled as ‘Manuscript’

• If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

The financial disclosure and updated statement included in the cover letter

Journal Requirements:When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE’s style requirements, including those for file naming.

Dear editor,

� We thank you for reminding us to check our manuscript in lines with PLOS ONE's style requirements. We checked journal formats and corrected it accordingly.

2. Please include additional information regarding the checklist and questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses.

For instance, if you developed a questionnaire and/or checklist as part of this study and it is not under copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

Dear editor,

We uploaded the questionnaire written in English, Afaan Oromo, and Amharic languages as supporting information.

� We confirm this does not alter our adherence to PLOS ONE policies on sharing data and materials.

Funding

This study obtained findings s from Addis Ababa University and Jimma University for data collection. The funding universities do not have any role in the study's design, data collection, analysis and interpretation of data and writing of the manuscript.

b. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

� We included the updated competing interest statement in our cover letter.

� The corresponding author declared on behalf of all authors

� The corresponding author linked his ORCID iD

� We included the updated list of authors and their corresponding affiliation as per request.

Response to Reviewers' comments:

We thank you for your invaluable comments, suggestions and recommendations. We have amended the manuscript based on your constructive comments as follows:

We thank you for raising this critical comment; although we mentioned purposive selection of the hospitals, we have included all hospitals except one. So, we feel it can be generalizable to the whole study area. Besides our indication of the limitations, we have now updated the revised manuscript indicating that almost all hospitals six out of seven in the study area were assessed.

Thank you again for your constructive comment. We just considered P-value for candidate selection. We used the 95% CI interval for the final decision to minimize complications/false positive rate. If the confidence interval includes a null value, we declared not statistically significant.

Thank you for the comment. We Now included the final regression formula as per your invaluable recommendation as follows.

log⁡(odds of CA)=-1.997+1.234(drug use)+1.368 (pesticide exposure)+1.412 (passive smoker)-0.358 (folic acid)+1.349 (history of CA+0.729 (surface water)+1.082 (no antenatal care visits)+0.752 (1 to 3 antenatal care visit).

� Thanks for the suggestion about the availability of data and materials.

We uploaded all required documents as supporting information including consent form and questionnaire written in the English, Afaan Oromo, and Amharic languages.

As per your recommendation and PLOS ONE standard of minimal data set, particularly in our manuscript, we a

Availability of data and materials

All relevant data are within the manuscript and its supporting information.

We have corrected.

Attachment

Submitted filename: Reponse to Reviewers.docx

Decision Letter 1

Linglin Xie

16 Dec 2020

PONE-D-20-23170R1

Risk factors associated with congenital anomalies among newborns in southwestern Ethiopia: A case-control study

PLOS ONE

Dear Dr. Geneti,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by 01/15/2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Linglin Xie

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The modifications are reasonable to all comments except the one for the multiple test issue. The multiple test issue would not be solved by replacing p-values with significance intervals. If a 95% CI is used, then significance level is still 5%. The authors should also adjust their significance levels and choose a more restrict CI to adjust for the multiple test issue.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jan 28;16(1):e0245915. doi: 10.1371/journal.pone.0245915.r004

Author response to Decision Letter 1


7 Jan 2021

Dear editor,

We thank you for your invaluable comments, suggestions and recommendations in our revised manuscript,

Now we included responses and corrections as per your comments and suggestions for each point raised either by the editor or the reviewer’s as follows

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

� The rebuttal letter is prepared and uploaded as a separate file and labeled ‘Response to Reviewers’

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'

� The changes made to the original version are highlighted in orange color in the revised manuscript. The file is labeled as ‘Revised Manuscript with Track Changes’.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

� The unmarked version of the revised paper without tracked changes labeled as ‘Manuscript’

• If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

� No changes made

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

________________________________________

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

________________________________________

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

________________________________________

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

________________________________________

5. Is the manuscript presented in an intelligible fashion and written in Standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

________________________________________

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The modifications are reasonable to all comments except the one for the multiple test issue. The multiple test issue would not be solved by replacing p-values with significance intervals. If a 95% CI is used, then significance level is still 5%. The authors should also adjust their significance levels and choose a more restrict CI to adjust for the multiple test issue.

Comment accepted:

Dear reviewer, we thank you for raising this critical comment. It is acceptable that instead of looking at the 95% CI, logistic regression analyses was repeated by using a narrower interval (e.g. 99% CI) to reduce the significance level from 0.05 to 0.01. Setting a higher significance threshold for individual comparisons to compensate for the number of inferences was being made. This is one way that we can reduce the probability of getting a false positive. Therefore, as per your invaluable comment, we corrected and adjusted the multiple tests to 99% confidence interval and significance level of 0.01(1%) and indicated it in the revised manuscript in (table 6 and 7) as well as in the text under independent predicator (risk factors) of congenital anomalies.

Interdependent risk factors adjusted for multiple tests are indicated and uploaded as supporting information as S2 Table for your considerations.

Best regards!

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Linglin Xie

11 Jan 2021

Risk factors associated with congenital anomalies among newborns in southwestern Ethiopia: A case-control study

PONE-D-20-23170R2

Dear Dr. Geneti,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Linglin Xie

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Linglin Xie

18 Jan 2021

PONE-D-20-23170R2

Risk factors associated with congenital anomalies among newborns in southwestern Ethiopia: A case-control study

Dear Dr. Abebe:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Linglin Xie

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Descriptive analysis (mean and Std.) Deviation of maternal and neonatal characteristics of the study participants in relation to birth weight, gestational age, birth order of the infancy, maternal age, paternal age, maternal average monthly income, party and gravida.

    (DOCX)

    S2 Table. Interdependent risk factors adjusted for multiple tests.

    (DOCX)

    S1 Annexes

    (DOCX)

    S1 File

    (SAV)

    S1 Syntax

    (SPS)

    Attachment

    Submitted filename: Reponse to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES